TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03138031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol alcohol injection
Description: Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required.
Study: NCT01032239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal baclofen
Description: ITB test, implant, 6 months follow-up
Study: NCT04089943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revascularization operation
Description: Participants will be randomized into an endovascular or open bypass procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Healthy non-PAD participants will be recruited for the study.
Study: NCT06503081

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy with video recording and biopsy collection
Study: NCT04509791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Human Thymocyte Immunoglobulin, Rabbit
Description: MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Human Thymocyte Immunoglobulin, Rabbit
Description: MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Human Thymocyte Immunoglobulin, Rabbit
Description: MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Human Thymocyte Immunoglobulin, Rabbit
Description: MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Human Thymocyte Immunoglobulin, Rabbit
Description: MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)
Study: NCT04103281

Intervention type: OTHER
Intervention: Sepsis
Description: Sepsis patients in the ICU with a breathing tube
Study: NCT03482557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CESM
Description: Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI uses magnets to create a detailed image of the tissues and bones inside of the body
Study: NCT01876186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin for 12 weeks
Description: Solifenacin 5 mg one a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin for 24 weeks
Description: Solifenacin 5 mg once a day for 24 weeks
Study: NCT02496091

Intervention type: DEVICE
Intervention: ATLANTIS Abutment
Study: NCT03261726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedEl Test Electrode Placer
Description: This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
Study: NCT02574052

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: participants' food choices
Description: just recorded the participants' food choices in the school cafeteria

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: menu labelling without nutrition education
Description: The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: menu labelling with nutrition education
Description: The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
Study: NCT01627873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
Study: NCT03265470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
Study: NCT04249089

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation video and pamplet
Description: This group will be asked to watch a video and perform relaxation techniques twice a day following surgery
Study: NCT04568681

Intervention type: DEVICE
Intervention: Deep brain stimulation (DBS)
Description: Deep brain stimulation is an FDA approved therapy that involves surgical implantation of electrodes in deep brain targets and an implantable pulse generator delivers electrical pulses.
Study: NCT01775033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
Study: NCT01443806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg, one time
Study: NCT02616692

Intervention type: DRUG
Intervention: Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]
Description: Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
Study: NCT02673164

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CSCC_ASC
Description: The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
Study: NCT03849443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product (1000 mg intravenous bolus)
Description: Intravenous methods to decrease blood loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C 250 MG Oral Tablet
Description: Oral method of placebo
Study: NCT02673164

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CSCC_ASC
Description: The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
Study: NCT03849443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 250 MG Oral Tablet
Description: Oral method of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 250 MG Oral Tablet
Description: Oral method of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 650Mg Tablet
Description: Oral method of treatment group
Study: NCT03036579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Duo
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celtra Duo
Description: Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
Study: NCT01820871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Management Using Smartphone Application for Type2 DM
Study: NCT03849443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 650Mg Tablet
Description: Oral method of treatment group
Study: NCT00287196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
Study: NCT02857400

Intervention type: OTHER
Group type: OTHER
Intervention: current standard of care
Description: connection documentation faxed to GP (General practitioner) on the day of patient's discharge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CREDO standard of care
Description: organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP
Study: NCT01471340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol MDI 100/5 mcg
Description: two inhalations BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol MDI 200/5 mcg
Description: two inhalations BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate MDI 100 mcg
Description: two inhalations BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate MDI 200 mcg
Description: two inhalations BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI
Description: use as needed for asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI
Description: use as needed for asthma symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/prednisolone
Description: Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/prednisolone
Description: Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
Study: NCT03341442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No hip precautions
Description: No hip precautions practiced after THA surgery
Study: NCT01813253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
Study: NCT04143737

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy lifestyle intervention
Description: 38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
Study: NCT01813253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg IV once weekly until progression or unacceptable toxicity develops
Study: NCT00618553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire regarding quality-of-life that lasts about 30 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Rehabilitation treatment given over about 3-4 weeks.
Study: NCT01953588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Fulvestrant 500 mg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Fulvestrant 500 mg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Anastrozole 1 mg oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Anastrozole 1 mg oral tablet
Study: NCT05304793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual management of dyspnea
Study: NCT03850912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eSyM App Usage
Description: Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eSyM App Usage
Description: Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM
Study: NCT05304793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Receive TAB treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03850912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SASS Questionnaire
Description: A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received.
Study: NCT05304793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03850912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SASS Questionnaire
Description: A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative Interview
Description: A small subset of eSyM- and eSyM+ patients will be invited to take part in follow-up qualitative interviews.
Study: NCT02754674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: type of anterior cruciate ligament reconstruction
Description: comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: type of anterior cruciate ligament reconstruction
Description: comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
Study: NCT03850912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative Interview
Description: A small subset of eSyM- and eSyM+ patients will be invited to take part in follow-up qualitative interviews.
Study: NCT03319342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Perform acts of kindness to others

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Perform acts of kindness to self

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Perform self-kindness meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Keep track of daily activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02797457

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bilateral allograft of the hands and forearms.
Description: Bilateral allograft of the hands and forearms.
Study: NCT01820871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-management using booklet for management type 2 DM
Study: NCT03387098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]
Study: NCT02065362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNR.NPC-specific T cells
Description: Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNR.NPC-specific T cells + cyclophosphamide + fludarabine
Description: Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2
Study: NCT02797457

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prosthetic forehands
Description: Prosthetic forehands
Study: NCT03387098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody
Study: NCT01872156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention GESTABAC
Description: Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The group control will act according to usual management.
Study: NCT02312609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride
Description: extended release tablets 135 mg
Study: NCT02609035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic prompt
Study: NCT04610645

Intervention type: DEVICE
Intervention: OCT
Description: 3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck

Intervention type: DEVICE
Intervention: Dermatoscope
Description: 2x2 pictures taken with a dermatoscope

Intervention type: GENETIC
Intervention: 3-Colour FISH
Description: Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
Study: NCT02733835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
Study: NCT01407302

Intervention type: OTHER
Intervention: Head rotation
Description: Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)

Intervention type: OTHER
Intervention: Head rotation
Description: Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
Study: NCT03473366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tao Mask
Description: All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
Study: NCT03387098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT04119050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion